NeuroDerm to Host Fourth Quarter and 2016 Fiscal Year Financial Results Conference Call on March 30, 2017
21 Mars 2017 - 12:00PM
NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical
company developing drug-device combinations for central nervous
system (CNS) disorders, today announced that it will report
financial results for the fourth quarter and fiscal year of 2016
before the market opens on Thursday, March 30, 2017. Management
will host a conference call beginning at 8:30 a.m. Eastern Time
that day to review results and provide a company update.
To access the call, dial 844-452-2810 (U.S.) or
574-990-9831 (outside of the U.S.). The passcode is 89081893. A
live webcast will be available in the Events and Presentations
section of the Investor Relations page at NeuroDerm.com. Please log
in approximately 5-10 minutes prior to the scheduled start
time.
The archived webcast will be available in the
Events and Presentations section of the company’s website.
About NeuroDermNeuroDerm is a
clinical-stage pharmaceutical company developing drug-device
combinations for central nervous system (CNS) disorders that are
designed to overcome major deficiencies of current treatments and
achieve enhanced clinical efficacy through continuous, controlled
administration. NeuroDerm has three product candidates in different
stages of development which offer a solution for almost every
Parkinson’s disease patient from the moderate to the very severe
stage of the disease. NeuroDerm has developed a line of levodopa
and carbidopa (LD/CD) product candidates administered through small
belt pumps that deliver a continuous, controlled dose of LD/CD. The
LD/CD product candidates are ND0612L and ND0612H, which are used
for treatment of moderate and advanced Parkinson’s disease
patients, respectively, and which are delivered subcutaneously. In
addition, NeuroDerm is developing ND0701, a novel subcutaneously
delivered apomorphine formulation for patients who suffer from
moderate to severe Parkinson’s disease and who do not respond well
to LD/CD. NeuroDerm is headquartered in the Weizmann Science Park
in Rehovot, Israel.
Forward-Looking StatementsThis
press release contains forward-looking statements, within the
meaning of the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995, Section 27A of the Securities Act of
1933, as amended, and Section 21E of the Securities Exchange Act of
1934, as amended that involve risks and uncertainties. Such
forward-looking statements may include projections regarding our
future performance and may be identified by words like
"anticipate," "assume," "believe," "continue," "could," "estimate,"
"expect," "intend," "may," "plan," "potential," "predict,"
"project," "future," "will," "seek" and similar terms or phrases.
The forward-looking statements contained in this press release are
based on management's current expectations and projections about
future events. There are important factors that could cause our
actual results, levels of activity, performance or achievements to
differ materially from the results, levels of activity, performance
or achievements expressed or implied by the forward-looking
statements. In particular, you should consider the risks provided
under "Risk Factors" in our annual report on Form 20-F for the year
ended December 31, 2015 filed with the Securities and Exchange
Commission. Any forward-looking statement made by us in this press
release speaks only as of the date hereof. Factors or events that
could cause our actual results to differ may emerge from time to
time, and it is not possible for us to predict all of them. We
undertake no obligation to publicly update any forward-looking
statements, whether as a result of new information, future
developments or otherwise.
NeuroDerm Contact:Oded S.
Lieberman, PhD, CEOoded@neuroderm.com Tel.: +972-8-946 2729;
Cell: +1-617-517 6077
U.S. Investor Contact:David
CareyLazar Partners
Ltd.dcarey@lazarpartners.com +212-867-1768
U.S. Media Contact:Erich
SandovalLazar Partners
Ltd.esandoval@lazarpartners.com +917-497-2867
NEURODERM LTD. (NASDAQ:NDRM)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
NEURODERM LTD. (NASDAQ:NDRM)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024